The local reimbursement application procedures in each of the partnering FaAP countries are briefly introduced below to facilitate cooperation between countries. Also, the financing agents, HTA bodies and MoHs are listed.
Key stakeholders in decision making
The table below helps to identify each stakeholder (Financing agent, HTA, Ministry of Health) in the reimbursement procedure of participating countries.
Czech Republic
Hungary
The local reimbursement process is initiated by the (or the representative of the) market authorization holder. The reimbursement dossier is submitted to the National Health Insurance Fund (NHIF). If the submission is eligible for a full procedure, the dossier is forwarded to he National Institute of Pharmacy and Nutrition (NIPN) for critical assessment, and the Board of Medical Professionals is invitited to provide a clinical opinion.
These opinions are consolidated on the meetings of the Technology Assessment Committee, which provides advice to the NHIF on the proposal for decision. The final decision maker is the Ministry of Health (Ministry of Human Capacities), which modifies the appropriate laws & publishes it in the Official Gazette to reimburse the appropriate products (also specifying further details, such as list of providers or indication).
Neither the opinion of the Board of Medical Professionals or NIPN are legally binding for the NHIF or the MoH. Information on the pharmaceutical market is fairly detailed (product-level information on list prices and consumption Rx pharma products), yet mostly available in Hungarian. The database of available products with their reimbursement status is available here. The regulatory database is available at this website.